Company Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Akeso, Inc.

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Hong Kong S.E. Other stock markets 01:38:20 26/04/2024 pm IST			5-day change	1st Jan Change
48.7 ^HKD	+0.52%		+10.93%	+4.96%

24/04	Akeso’s Supplemental New Drug Application for Cervical Cancer Drug Accepted by Chinese Regulator	MT
24/04	National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer	CI

Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.

Number of employees: 2,778

HKD in Million	2021	Weight	2022	Weight	Delta
Therapies 100.0 %	272	100.0 %	974	100.0 %	+258.22%

HKD in Million	2021	Weight	2022	Weight	Delta
China 100.0 %	117	43.0 %	974	100.0 %	+733.01%

Managers	Title	Age	Since
Baiyong Li FOU	Founder	56	19/12/19
Peng Zhang FOU	Founder	48	19/12/19
Michelle Xia CEO	Chief Executive Officer	58	19/12/19
Zhongmin Wang FOU	Founder	55	19/12/19
Hui Xin Liang SEC	Corporate Secretary	-	23/22/23
Michael Chen PRN	Corporate Officer/Principal	-	30/20/30
Xin Feng Zhang PRN	Corporate Officer/Principal	-	17/20/17

Members of the board	Title	Age	Since
Bo Tan BRD	Director/Board Member	51	01/20/01
Zhongmin Wang FOU	Founder	55	19/12/19
Yan Xu BRD	Director/Board Member	60	-
Michelle Xia CEO	Chief Executive Officer	58	19/12/19
Baiyong Li FOU	Founder	56	19/12/19
Jun Wen Zeng BRD	Director/Board Member	63	-
Yu Xia BRD	Director/Board Member	54	-
Yi Zhou BRD	Director/Board Member	44	01/19/01
Rong Gang Xie BRD	Director/Board Member	39	19/20/19

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	865,857,176	634,964,039 ( 73.33 %)	0	73.33 %

Name	Equities	%	Valuation
Xia Yu Family 6.869 %	57,771,042	6.869 %	344 M $
Green Court Capital Management Ltd. 5.167 %	43,453,668	5.167 %	259 M $
Li Bai Yong Family 5.082 %	42,738,554	5.082 %	255 M $
Shenzhen Capital Group Co., Ltd. 5.000 %	42,052,529	5.000 %	251 M $
Xun Zheng 4.979 %	41,874,000	4.979 %	250 M $
Zhang Peng Family 4.153 %	34,929,065	4.153 %	208 M $
Zhongmin Wang 3.744 %	31,492,881	3.744 %	188 M $
Michelle Xia 2.497 %	21,000,000	2.497 %	125 M $
Luo Wenfeng 1.713 %	14,406,217	1.713 %	86 M $
Wang Zhong Min Family 1.630 %	13,706,442	1.630 %	82 M $

Akeso, Inc.

Torch Development Zone No.6 Shennong Road

528437, Zhongshan

http://www.akesobio.com/en/

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.08 CNY

Average target price

55.44 CNY

Spread / Average Target

+22.97%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
AKESO, INC.	+4.96%	5.39B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs